I hope you are right. On Sun, Feb 22, 2009 at 08:54:53PM -0000, Simon Ward wrote: > The Biotech model is experiencing severe problems at present given that > it's built on credit secured on the promise of future earnings. With drugs > being pressured both by genetrics and by a seeming inability to turn gene > mapping into successful products, the credit, be it debt or shares, appears > to be drying up. > > The next few years will be a period of intense M&A activity in the pharma > industry and it'll make an interesting study of capital movement in a > crisis situation. > > Simon Ward > _______________________________________________ > pen-l mailing list > [email protected] > https://lists.csuchico.edu/mailman/listinfo/pen-l
-- Michael Perelman Economics Department California State University Chico, CA 95929 Tel. 530-898-5321 E-Mail michael at ecst.csuchico.edu michaelperelman.wordpress.com _______________________________________________ pen-l mailing list [email protected] https://lists.csuchico.edu/mailman/listinfo/pen-l
